G1 Therapeutics (GTHX) Revenue & Revenue Breakdown
G1 Therapeutics Revenue Highlights
Latest Revenue (Y)
$82.51M
Latest Revenue (Q)
$16.55M
Main Segment (Y)
Product
G1 Therapeutics Revenue by Period
G1 Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $82.51M | 60.84% |
| 2022-12-31 | $51.30M | 62.98% |
| 2021-12-31 | $31.48M | -30.49% |
| 2020-12-31 | $45.28M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | -100.00% |
| 2015-12-31 | $522.00K | -49.94% |
| 2014-12-31 | $1.04M | - |
G1 Therapeutics generated $82.51M in revenue during NA 2023, up 60.84% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
G1 Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $16.55M | 14.30% |
| 2024-03-31 | $14.48M | -2.67% |
| 2023-12-31 | $14.87M | 20.92% |
| 2023-09-30 | $12.30M | -70.99% |
| 2023-06-30 | $42.39M | 227.45% |
| 2023-03-31 | $12.95M | 26.30% |
| 2022-12-31 | $10.25M | -56.52% |
| 2022-09-30 | $23.58M | 122.98% |
| 2022-06-30 | $10.57M | 53.19% |
| 2022-03-31 | $6.90M | 19.08% |
| 2021-12-31 | $5.80M | 19.31% |
| 2021-09-30 | $4.86M | -26.44% |
| 2021-06-30 | $6.60M | -53.55% |
| 2021-03-31 | $14.22M | -14.07% |
| 2020-12-31 | $16.55M | -37.79% |
| 2020-09-30 | $26.60M | 1142.94% |
| 2020-06-30 | $2.14M | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $103.21M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
G1 Therapeutics generated $16.55M in revenue during Q2 2024, up 14.30% compared to the previous quarter, and up 127.81% compared to the same period a year ago.
G1 Therapeutics Revenue Breakdown
G1 Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Product | $46.34M | $31.34M | $11.12M | - |
| License | $36.17M | $19.96M | $20.36M | - |
| Cost Reimbursements | - | - | - | $1.30M |
G1 Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (56.17%), and License (43.83%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $14.08M | $13.92M | $10.84M | $11.09M | $10.49M | $8.87M | $8.27M | $8.72M | $5.48M | $4.40M | $3.58M | $2.53M | $609.00K | - |
| License | $397.00K | $951.00K | $1.46M | $31.30M | $2.45M | $1.38M | $15.31M | $1.85M | $1.42M | $1.39M | $1.28M | $4.07M | $13.61M | - |
| Cost Reimbursements | - | - | - | - | - | - | - | - | - | - | - | - | - | $600.00K |
G1 Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (97.26%), and License (2.74%).
G1 Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| AXSM | Axsome Therapeutics | $270.60M | $87.17M |
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| PBYI | Puma Bio | $235.64M | $47.08M |
| SGMO | Sangamo Therapeutics | $176.23M | $356.00K |
| HRTX | Heron Therapeutics | $127.04M | $46.54M |
| RCUS | Arcus Biosciences | $117.00M | $39.00M |
| GTHX | G1 Therapeutics | $82.51M | $16.55M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| MGNX | MacroGenics | $58.75M | $10.80M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| ATRA | Atara Biotherapeutics | $8.57M | $28.64M |
| ALLO | Allogene Therapeutics | $95.00K | $22.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| ANNX | Annexon | - | - |
| LRMR | Larimar Therapeutics | - | - |
| SANA | Sana Bio | - | - |
GTHX Revenue FAQ
What is G1 Therapeutics’s yearly revenue?
G1 Therapeutics's yearly revenue for 2023 was $82.51M, representing an increase of 60.84% compared to 2022. The company's yearly revenue for 2022 was $51.3M, representing an increase of 62.98% compared to 2021. GTHX's yearly revenue for 2021 was $31.48M, representing a decrease of -30.49% compared to 2020.
What is G1 Therapeutics’s quarterly revenue?
G1 Therapeutics's quarterly revenue for Q2 2024 was $16.55M, a 14.30% increase from the previous quarter (Q1 2024), and a -60.97% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $14.48M, a -2.67% decrease from the previous quarter (Q4 2023), and a 11.82% increase year-over-year (Q1 2023). GTHX's quarterly revenue for Q4 2023 was $14.87M, a 20.92% increase from the previous quarter (Q3 2023), and a 45.10% increase year-over-year (Q4 2022).
What is G1 Therapeutics’s revenue growth rate?
G1 Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 162.14%, and for the last 5 years (2019-2023) was 0%.
What are G1 Therapeutics’s revenue streams?
G1 Therapeutics's revenue streams in c 23 are Product, and License. Product generated $46.34M in revenue, accounting 56.17% of the company's total revenue, up 47.89% year-over-year. License generated $36.17M in revenue, accounting 43.83% of the company's total revenue, up 81.16% year-over-year.
What is G1 Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of G1 Therapeutics was Product. This segment made a revenue of $46.34M, representing 56.17% of the company's total revenue.